MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-08-2023
Horizon Therapeutics Public Limited Company DIO Ratio 2011-2026 | HZNP
Annual DIO Ratio Horizon Therapeutics Public Limited Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 78.4 | 69.1 | 44.2 | 54.2 | 51.6 | 54.1 | 172 | 38.4 | 96.8 | 250 | 150 | 60.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 250 | 38.4 | 93.2 |
Quarterly DIO Ratio Horizon Therapeutics Public Limited Company
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 69.5 | 73.1 | - | 37.1 | 44.9 | 95.9 | - | 90 | 113 | 143 | - | 45.4 | 56.5 | 60.5 | - | 54.6 | 55.1 | 54.1 | 47 | 50.9 | 50.7 | 46.5 | 39.3 | 44.9 | 43.3 | 77.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 143 | 37.1 | 63.3 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.88 | -2.07 % | $ 6.47 M |  China |
 |
ACADIA Pharmaceuticals
ACAD
|
295 | $ 22.67 | 1.66 % | $ 3.76 B | USA |
 |
BioDelivery Sciences International
BDSI
|
321 | - | -4.8 % | $ 255 M | USA |
 |
CASI Pharmaceuticals
CASI
|
47.4 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
69.7 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
Aquestive Therapeutics
AQST
|
120 | $ 4.09 | -0.24 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
185 | $ 23.29 | -0.56 % | $ 2.96 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.48 | 4.23 % | $ 394 M | Britain |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
125 | - | - | $ 546 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
38.1 | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
1.56 K | $ 1.06 | -2.75 % | $ 12.9 M | USA |